Clinical Trials on Transitional Cell Carcinoma in New Zealand

Total 7833 results

Xencor, Inc.
ICON plc

Terminated

Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer

Small Cell Lung Cancer | Merkel Cell Carcinoma

United States
Neal Ready
Merck Sharp & Dohme LLC

Active, not recruiting

Neoadjuvant Pembrolizumab (TOP 1501)

Non-small Cell Lung Carcinoma

United States
Ludwig Institute for Cancer Research
Xcovery Holding Company, LLC; Cancer Research Institute, New York City; MedImmune...

Completed

Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer

Carcinoma | NSCLC | Non-small Cell Lung Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
AstraZeneca

Withdrawn

Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients

Oropharynx Cancer | HPV-Related Carcinoma | HPV Positive Oropharyngeal Squamous Cell Carcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) With Osimertinib for the Treatment of Patients With Oligoprogressive EGFR Positive Non-small Cell Lung Carcinoma

Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Endometrioid Adenocarcinoma | Ovarian Undifferentiated Carcinoma | Fallopian Tube Carcinoma | Ovarian Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell... and other conditions

United States
Icahn School of Medicine at Mount Sinai
Merck Sharp & Dohme LLC; Celldex Therapeutics

Recruiting

Vaccination With Flt3L, Radiation, and Poly-ICLC

Non-Hodgkin's Lymphoma | Metastatic Breast Cancer | Head and Neck Squamous Cell Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer

Extensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell Carcinoma | Platinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Recurrent Lung Small Cell Carcinoma

United States
Washington University School of Medicine
Pfizer

Completed

PD 0332991 and Cetuximab in Patients With Incurable SCCHN

Carcinoma, Squamous Cell of Head and Neck

United States
Yale University
National Cancer Institute (NCI)

Terminated

Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer

Kidney Cancer | Head and Neck Cancer | Lung Cancer | Brain and Central Nervous System Tumors | Intraocular Melanoma | Melanoma (Skin) | Pheochromocytoma | Islet Cell Tumor | Gastrointestinal Carcinoid Tumor | Neoplastic Syndrome | Neuroendocrine Carcinoma of the Skin | Childhood Langerhans Cell Histiocytosis

United States
Konstantin Dragnev
Genentech, Inc.; Ligand Pharmaceuticals

Completed

Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer

Carcinoma, Non-small-cell Lung

United States
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer

Adenocarcinoma of the Gastroesophageal Junction | Squamous Cell Carcinoma of the Esophagus | Adenocarcinoma of the Esophagus | Recurrent Esophageal Cancer | Stage IV Esophageal Cancer | Stage III Esophageal Cancer

United States
Memorial Sloan Kettering Cancer Center
Curadev Pharma

Recruiting

A Study of CRD3874-SI in People With Solid Tumors

Sarcoma | Merkel Cell Carcinoma

United States
Calithera Biosciences, Inc

Completed

CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma (CANTATA)

Metastatic Renal Cell Carcinoma | Advanced Renal Cell Carcinoma

United States, United Kingdom, Australia, France, Italy, Germany, Spain, New Zealand
National Cancer Institute (NCI)

Recruiting

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma

United States
University of Warwick
University of Oxford; Cancer Research UK; University of Birmingham

Unknown

Determination of Cetuximab Versus Cisplatin Early and Late Toxicity Events in HPV+ OPSCC (De-ESCALaTE)

Oropharyngeal Squamous Cell Carcinoma

Ireland, United Kingdom, Netherlands
NYU College of Dentistry

Recruiting

Dissecting the Heterogeneity of Oral Cancer Pain

Oral Squamous Cell Carcinoma

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Comparing High-Dose Cisplatin Every Three Weeks to Low-Dose Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

Advanced Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of Unknown Primary | Advanced Hypopharyngeal Squamous Cell Carcinoma | Advanced Laryngeal Squamous Cell Carcinoma | Advanced Oropharyngeal Squamous Cell Carcinoma

United States, Canada
Keythera Pharmaceuticals (Australia) Pty Ltd

Recruiting

A Study of KF-0210 in Advanced Solid Tumors Patients

Gastric Cancer | Colorectal Cancer | Lung Cancer | Bladder Cancer | Advanced Solid Tumor | Squamous Cell Carcinoma of the Esophagus

Australia
Regeneron Pharmaceuticals

Active, not recruiting

CemiplimAb Survivorship Epidemiology (CASE)

Basal Cell Carcinoma | Cutaneous Squamous Cell Carcinoma

United States, Puerto Rico
Alpha Tau Medical LTD.

Recruiting

A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma

Recurrent Squamous Cell Carcinoma

United States, Israel, Canada
ALX Oncology Inc.
Merck Sharp & Dohme LLC

Recruiting

Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma

United States, Korea, Republic of, United Kingdom, Spain, Belgium, Singapore, Canada, Netherlands, Australia
Celldex Therapeutics

Terminated

A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma

Neoplasms | Neoplasms by Histologic Type | Kidney Neoplasms | Carcinoma, Renal Cell | Urologic Neoplasms | Urogenital Neoplasms | Kidney Diseases | Urologic Diseases | Clear-cell Metastatic Renal Cell Carcinoma

United States
Melanoma Institute Australia
Bristol-Myers Squibb

Recruiting

Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma

Merkel Cell Carcinoma

Australia
Sharmila Anandasabapathy, MD
William Marsh Rice University

Terminated

Optical Imaging of Head and Neck Cancer

Head and Neck Cancer | Squamous Cell Carcinoma | Neoplasia

United States
Iovance Biotherapeutics, Inc.

Completed

Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck

Squamous Cell Carcinoma of the Head and Neck

United States
Australian and New Zealand Urogenital and Prostate...
Bristol-Myers Squibb

Active, not recruiting

Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602) (UNISoN)

Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Papillary Renal Cell Carcinoma Type 1 | Papillary Renal Cell Carcinoma Type 2 | Chromophobe Renal Cell Carcinoma | Xp11 Translocation Carcinoma

Australia
Kura Oncology, Inc.

Recruiting

Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

HNSCC

United States
Celldex Therapeutics

Terminated

A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Advanced Head and Neck Squamous Cell Carcinoma

United States
Memorial Sloan Kettering Cancer Center
Varian Medical Systems

Recruiting

A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue

Melanoma | Sarcoma | Renal Cell Carcinoma | Pancreatic Cancer | NSCLC | Non Small Cell Lung Cancer | Bladder Cancer | Metastatic Solid Tumor | Gastrointestinal Cancer | Lobular Breast Carcinoma | Invasive Ductal Breast Carcinoma | Gastrointestinal Adenocarcinoma | Invasive Ductal Breast Carcinoma Stage IV | Lobular... and other conditions

United States
UroGen Pharma Ltd.

Terminated

A Phase 3 Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (ATLAS)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma

United States, Israel, Russian Federation, Georgia, Bulgaria, Estonia, Latvia, Poland, Serbia, Ukraine
Novartis Pharmaceuticals

Completed

EPO906 in Carcinoid and Other Neuroendocrine Tumors

Neuroendocrine Tumors | Carcinoid

United States
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)

NSCLC | Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | Non-small Cell Carcinoma

United States
Pfizer

Completed

Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Post-alectinib Treatment Patterns

Non-Small-Cell Lung Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck

Head and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oral Cavity Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Metastatic... and other conditions

United States
Roswell Park Cancer Institute
NeuroEndocrine Tumor Research Foundation (NETRF)

Recruiting

Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

Lung Atypical Carcinoid Tumor | Metastatic Pancreatic Neuroendocrine Tumor | Lung Typical Carcinoid Tumor

United States
UroGen Pharma Ltd.

Active, not recruiting

A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer (ENVISION)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma

United States, Spain, Lithuania, Georgia, Bulgaria, Estonia, Latvia, Poland, Serbia, Austria
Exelixis
Arcus Biosciences, Inc.

Recruiting

Study of Zanzalintinib (XL092) + AB521 and Zanzalintinib + AB521 + Nivolumab in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Other Advanced Solid Tumors (STELLAR-009)

Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors

United States
National Cancer Institute (NCI)

Completed

Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer

Advanced Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Advanced Sarcomatoid Renal Cell Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Metastatic Kidney Carcinoma

United States
Roswell Park Cancer Institute
Novartis

Terminated

Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer

United States
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)

Renal Cell Carcinoma | Clear-cell Metastatic Renal Cell Carcinoma

United States, Canada
National Cancer Institute (NCI)

Recruiting

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Collecting Duct Carcinoma | Kidney Medullary Carcinoma | Advanced Renal Cell Carcinoma | Unclassified Renal Cell Carcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy

Mucositis | Tongue Cancer | Oral Complications | Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous Cell Carcinoma of the Oropharynx | Recurrent Verrucous Carcinoma of the Larynx | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage III Hypopharyngeal Carcinoma AJCC v8 | Stage III Laryngeal Cancer AJCC v8 | Stage III Lip and Oral Cavity Cancer AJCC v8 | Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Stage IVA Lip and Oral... and other conditions

United States, Canada
Seagen Inc.
Merck Sharp & Dohme LLC

Terminated

Safety Study of SEA-CD40 in Cancer Patients

Melanoma | Lymphoma | Lymphoma, Follicular | Lymphoma, B-Cell | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin | Carcinoma, Non-Small-Cell Lung | Carcinoma, Squamous Cell | Neoplasm Metastasis | Hodgkin Disease | Pancreatic Adenocarcinoma | Non-Small Cell Lung Cancer | Squamous Cell Carcinoma of the Head... and other conditions

United States
Rain Oncology Inc

Terminated

Study for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin

Metastatic Head-and-neck Squamous-cell Carcinoma

United States, Australia
Vaccinex Inc.
Merck Sharp & Dohme LLC

Recruiting

Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE-B84)

Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)

United States
NYU Langone Health

Terminated

Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

United States
RTOG Foundation, Inc.
Merck Sharp & Dohme LLC

Recruiting

SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma (KEYSTROKE)

Head and Neck Squamous Cell Carcinoma (HNSCC)

Canada, United States

Clinical Trials on Transitional Cell Carcinoma in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Panama

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations